CBG (cannabigerol) is a non-psychoactive compound found in the cannabis plant that has drawn increasing medical interest for its anti-inflammatory, neuroprotective, and antibacterial properties. Unlike THC, it won’t get you high. What makes CBG unique among cannabinoids is its role as a chemical precursor: the cannabis plant produces CBG’s acid form (CBGA) first, then converts it into THC, CBD, and other cannabinoids. This has earned CBG the nickname “the mother cannabinoid.”
Why CBG Is Called the Mother Cannabinoid
Every major cannabinoid in the cannabis plant starts as CBGA, the acid form of CBG. The plant synthesizes CBGA from two simpler molecules, then specific enzymes convert it into the acid forms of THC, CBD, and CBC. Heat and time then strip off a carbon group (a process called decarboxylation) to produce the final active compounds. CBG itself is what’s left over when CBGA doesn’t get converted into something else.
This is why most mature cannabis plants contain very little CBG, often less than 1%. By the time the plant is harvested, most of its CBGA has already been transformed. Breeders have developed special high-CBG strains that limit this conversion, making it possible to extract CBG in useful quantities.
How CBG Interacts With the Body
CBG works through the endocannabinoid system, the same network of receptors that THC and CBD target, but it hits those receptors differently. It binds to both CB1 receptors (concentrated in the brain) and CB2 receptors (found mainly in the immune system) with low micromolar affinity. In cells that express both receptor types simultaneously, CBG shows a notable preference for CB2, with binding affinity jumping to around 56 nanomolar. This CB2 preference helps explain why CBG appears to influence inflammation without producing a high.
CBG also acts on targets outside the cannabinoid system. It activates alpha-2 adrenergic receptors at very low concentrations and blocks serotonin 1A receptors. The alpha-2 activity may contribute to its effects on blood pressure and pain signaling, while the serotonin receptor interaction distinguishes it from CBD, which activates those same serotonin receptors rather than blocking them. This opposite action on serotonin pathways is one of the clearest pharmacological differences between the two compounds.
CBG and Gut Inflammation
Some of the most promising preclinical research on CBG involves inflammatory bowel conditions. In a mouse model of colitis, daily treatment with a high-CBG hemp extract dramatically reduced disease severity. Treated animals had longer colons (a sign of less tissue damage), lower disease activity scores, and less visible damage to colon tissue compared to untreated animals.
The benefits went deeper than surface-level healing. Metabolic analysis of the treated mice showed that CBG helped normalize several biochemical pathways disrupted by intestinal inflammation, including those involved in tryptophan and amino acid metabolism. Colitis typically depletes key protective compounds in the gut. One of these, indole 3-acetic acid, is produced by gut bacteria and helps dial down inflammatory responses. Mice receiving CBG maintained higher levels of this compound, suggesting the extract helped preserve a healthier gut environment. These are animal findings, and human trials are still needed, but the breadth of the metabolic effects is notable.
Neuroprotective Effects
CBG has shown the ability to protect brain cells in animal models of neurodegenerative disease, particularly those mimicking Huntington’s disease. In mice given a neurotoxin that destroys the same brain region affected in Huntington’s, CBG treatment prevented more than 50% of the neuronal death that typically occurs. The treated mice also showed improvements in motor symptoms, including reduced limb clasping and less involuntary muscle contraction.
Results were more modest in a genetic model of Huntington’s (R6/2 transgenic mice, which more closely mirror the progressive nature of the human disease). CBG produced a small but statistically significant improvement in motor coordination, with treated mice staying on a rotating rod longer than untreated ones at every time point measured. However, it did not reverse the loss of a key neuronal marker in the striatum, suggesting CBG may slow functional decline without fully preventing the underlying cell death in this more aggressive model.
Effects on Eye Pressure
CBG is one of several cannabinoids confirmed to lower intraocular pressure, the primary risk factor in glaucoma. The mechanism likely involves reducing the production of fluid inside the eye. Cannabinoids appear to inhibit calcium flow into cells in the ciliary body (the structure that produces eye fluid), which reduces the release of a signaling chemical called noradrenaline and slows fluid production. There’s also evidence that cannabinoids widen blood vessels in the front of the eye, improving drainage of fluid through an alternative pathway.
Early studies on marijuana and eye pressure found a 25 to 30% reduction from smoking, though that effect came from THC. CBG’s specific contribution to pressure reduction has been confirmed in research but not yet quantified as precisely in human subjects.
How CBG Differs From CBD
CBG and CBD are both non-psychoactive, both come from the same precursor molecule, and both interact with CB1 and CB2 receptors at roughly similar strengths. The meaningful differences are in what they do at other targets. CBD activates serotonin 1A receptors, which is thought to underlie some of its anti-anxiety effects. CBG blocks those same receptors. This makes them pharmacologically complementary rather than interchangeable, and it means they could have quite different effects on mood and anxiety despite their surface-level similarities.
CBG’s strong activity at alpha-2 adrenergic receptors, effective at a fraction of a nanomolar, is another distinguishing feature. CBD does not share this property. Alpha-2 receptors play roles in pain modulation, blood pressure regulation, and sedation, which may explain some of the relaxation and pain-relief effects that CBG users report.
How the Body Absorbs CBG
Oral bioavailability of CBG sits around 28%, meaning roughly a quarter of what you swallow reaches your bloodstream. This is comparable to CBD’s oral bioavailability. Pharmacokinetic research (conducted in horses, one of the few species with formal data) found that how you take CBG affects how quickly it kicks in, though not necessarily how much your body ultimately absorbs.
A water-soluble micellar formulation reached peak blood levels in about 4 hours, while a standard oil-based formulation took closer to 9.5 hours. Total absorption was similar between the two. If faster onset matters to you, water-soluble CBG products may have an advantage over oil-based ones, even though you’ll absorb about the same total amount either way.
Safety and Side Effects
Human safety data on CBG is still limited, but early results are reassuring. The first clinical trial involving CBG tested a formulation containing 100 mg of CBG per day (split into two doses) alongside CBD and other ingredients in healthy adults. The study reported good safety and tolerability, with only one adverse event in the active group: diarrhea.
A separate survey of people using a CBG-predominant product found that the most common side effects were dry mouth (16.5% of respondents), sleepiness (15%), and increased appetite (11.8%). These mirror the side effect profile of CBD and are generally mild. The same survey reported that users noticed decreased fatigue, improved focus, and reduced anxiety. These are self-reported outcomes, not controlled trial results, but they paint a consistent early picture of CBG as well-tolerated at the doses currently found in consumer products.